Holen Sie sich die Stockscreener-App
3.53
0.28%
-0.01
Handel nachbörslich:
3.57
0.04
+1.13%
Schlusskurs vom Vortag:
$3.54
Offen:
$3.51
24-Stunden-Volumen:
1.28M
Relative Volume:
0.29
Marktkapitalisierung:
$575.60M
Einnahmen:
$296.15M
Nettoeinkommen (Verlust:
$24.02M
KGV:
29.27
EPS:
0.1206
Netto-Cashflow:
$127.01M
1W Leistung:
+9.29%
1M Leistung:
+0.86%
6M Leistung:
+138.51%
1J Leistung:
+163.43%
1-Tages-Spanne:
$3.49
$3.65
1-Wochen-Bereich:
$3.27
$3.93
52-Wochen-Spanne:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.53 | 577.23M | 296.15M | 24.02M | 127.01M | 0.1206 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-08 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-09 | Eingeleitet | Jefferies | Buy |
| 2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-02 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Eingeleitet | Northland Capital | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
| 2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
| 2017-04-07 | Bestätigt | Mizuho | Buy |
| 2017-02-22 | Bestätigt | Barclays | Equal Weight |
| 2016-11-04 | Bestätigt | Mizuho | Buy |
| 2016-10-24 | Bestätigt | Wedbush | Neutral |
| 2016-10-10 | Bestätigt | Mizuho | Buy |
| 2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
Ironwood (IRWD) is one of the most attractive small-cap drug manufacturers, here is why - MSN
Ironwood Pharmaceuticals (IRWD) price target increased by 10.31% to 5.46 - MSN
Support Test: Does Ironwood Pharmaceuticals Inc have consistent dividend growth2026 EndofMonth & High Win Rate Trade Tips - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 5.8%Time to Sell? - MarketBeat
IRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Ironwood (IRWD) is One of the Most Attractive Small-Cap Drug Manufacturers, Here is Why - Yahoo Finance
Range Financial Group LLC Acquires Shares of 426,095 Ironwood Pharmaceuticals, Inc. $IRWD - marketbeat.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 5.4%Still a Buy? - MarketBeat
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock? - Yahoo Finance
IRWD (Ironwood Pharmaceuticals) Net Income (Discontinued Op - GuruFocus
IRWD (Ironwood Pharmaceuticals) Inventories, Raw Materials & Components : $0.0 Mil (As of Dec. 2025) - GuruFocus
Aug Update: Can Ironwood Pharmaceuticals Inc outperform in the next rallyMarket Performance Recap & Technical Analysis for Trade Confirmation - baoquankhu1.vn
The Vanguard Group (NASDAQ: IRWD) reports zero beneficial ownership after realignment - Stock Titan
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report? - Yahoo Finance
Ironwood Pharmaceuticals (IRWD) Tops Small-Cap Growth List - gurufocus.com
IRWD Stock Price, Quote & Chart | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Sarissa Capital Management LP Reduces Stake in Ironwood Pharmace - GuruFocus
Ironwood Pharmaceuticals | 10-K: FY2025 Annual Report - Moomoo
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 9%Time to Buy? - marketbeat.com
Gastroparesis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma - Barchart
Will Linzess continue to aid IRWD's top line in 2026 after a soft Q4? - MSN
Market Pulse: Is Ironwood Pharmaceuticals Inc forming a breakout patternCEO Change & Scalable Portfolio Growth Methods - baoquankhu1.vn
Craig-Hallum Sticks to Its Buy Rating for Ironwood Pharma (IRWD) - The Globe and Mail
Sarissa Capital (IRWD) cuts Ironwood stake with 6.7M-share sale, keeps 5.8% - Stock Titan
Aug Rallies: Is Ironwood Pharmaceuticals Inc affected by consumer sentiment2026 Trade Ideas & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Pullback Watch: How much upside does Ironwood Pharmaceuticals Inc have2026 Intraday Action & Weekly High Return Stock Forecasts - baoquankhu1.vn
Insider Selling: Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Sells 6,730,800 Shares of Stock - MarketBeat
Ironwood Pharmaceuticals director Denner sells $20.5m in shares By Investing.com - Investing.com Canada
Ironwood Pharmaceuticals director Denner sells $20.5m in shares - Investing.com
Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale - Stock Titan
Breakouts Watch: Is Ironwood Pharmaceuticals Incs growth already priced in2026 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Up 15.8% in February - MarketBeat
Trade Report: Can Ironwood Pharmaceuticals Inc outperform in the next rallyWeekly Trade Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Ironwood hits 52-week high as AbbVie-partnered Linzess boosts 2026 outlook - MSN
Ironwood Pharmaceuticals (IRWD) CLO receives 136,612-share RSU grant - Stock Titan
Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant - Stock Titan
Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award - Stock Titan
Ironwood (IRWD) SVP and CMO awarded 136,612-share RSU performance grant - Stock Titan
Ironwood (IRWD) accounting chief granted 163,934 RSUs in stock award - Stock Titan
Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award - Stock Titan
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - TradingView
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD) - The Globe and Mail
Ironwood Pharma Maintains Revolving Credit Facility to 2028 - The Globe and Mail
Ironwood Pharmaceuticals, Inc. 8-K SEC Filing Details – Company Information, Address, and Nasdaq Listing - Minichart
Ironwood Pharmaceuticals confirms liquidity conditions for credit facility maturity - Investing.com
Ironwood Pharmaceuticals confirms liquidity conditions for credit facility maturity By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals Satisfies Liquidity Conditions In Credit Agreement On March 10 - TradingView
Ironwood Pharmaceuticals, Inc. Notifies Wells Fargo Bank, National Association of Satisfaction of Liquidity Conditions Under Amended Credit Agreement - marketscreener.com
Ironwood (NASDAQ: IRWD) confirms revolving credit facility maturity in 2028 - Stock Titan
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ironwood Pharmaceuticals Inc-Aktie (IRWD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| John Minardo | Chief Legal Officer |
Feb 24 '26 |
Sale |
3.66 |
19,053 |
69,734 |
363,886 |
| John Minardo | Chief Legal Officer |
Feb 23 '26 |
Sale |
3.81 |
17,439 |
66,443 |
382,939 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 23 '26 |
Sale |
3.81 |
15,570 |
59,322 |
538,437 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,239 |
41,135 |
213,738 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,287 |
39,193 |
224,977 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 24 '26 |
Sale |
3.66 |
103,526 |
378,905 |
1,489,002 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 23 '26 |
Sale |
3.81 |
94,757 |
361,024 |
1,592,528 |
| Martini Gregory S. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,457 |
41,933 |
160,601 |
| Martini Gregory S. | Chief Financial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,487 |
39,955 |
172,058 |
| Silver Ronald | Principal Accounting Officer |
Feb 24 '26 |
Sale |
3.66 |
12,621 |
46,193 |
252,636 |
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):